Roche announce UK sites for phase three clinical trial

Roche announce UK sites for phase three clinical trial

In December 2017 IONIS announced their phase one clinical trial for a Huntingtin Lowering or ‘gene silencing treatment’ had produced promising results.

For a reminder follow the link below.

They also announced that pharmaceutical company Roche purchased the licence to continue to develop this potential treatment for HD.

Last year, Roche announced that the phase three trial would commence early in 2019 and today they have revealed the UK sites that will participate. These are:

Aberdeen – Aberdeen Royal Infirmary

Birmingham – Birmingham and Solihull Mental Health Foundation Trust

Cambridge – Cambridge Centre for Brain Repair

Cardiff – University Hospital of Wales

Glasgow – Queen Elizabeth University Hospital Glasgow

Leeds – Leeds General Infirmary

London – National Hospital for Neurology and Neurosurgery

Manchester – Central Manchester University Hospitals NHS Foundation Trust

Oxford – John Radcliffe Hospital

Sheffield – Sheffield Children’s NHS Trust

Southampton – University Hospital Southampton NHS Foundation Trust

We are incredibly excited that there will be two Scottish sites: Aberdeen and Glasgow and our congratulations go to Professor Zosia Miedzybrodzka and Dr Stuart Ritchie who are the Principal Investigators and their teams.

Although the Aberdeen and Glasgow site will begin recruitment soon, they are not open yet and the majority of people recruited will be drawn from those already participating in ENROLL HD.

If you would like more information about the study you can contact the Roche UK Medical Information team for more information on:  0800 3281629 or

You can read more about the trial here

If you would like a refresher on how this treatment works, you can view this excellent article over at HD Buzz

Author: John Eden

John Eden


Leave a reply